Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced Dyskinesia

PROJECT SUMMARY/ABSTRACT:
L-DOPA remains the gold-standard treatment for Parkinson’s disease (PD). Unfortunately, within a decade of
commencing L-DOPA, nearly 90% of PD patients develop intractable abnormal involuntary movements known as L-
DOPA-induced dyskinesias (LID), severely impacting quality of life. Research implicates serotonin (5-HT) neurons
as a source of LID as they can take up L-DOPA, convert it to dopamine (DA), and release DA as an unregulated
“false neurotransmitter” leading to a dyskinesogenic phenotype. Although treatments aimed at alleviating LID have
emerged, only a minority of patients benefit due to their cost, side effects and/or invasiveness. Moreover, we
have yet to find a way to prevent LID development, in part due to major gaps in knowledge on how L-DOPA
treatment instigates maladaptive 5-HT reorganization and aberrant striatal output. Our research team has
recently collected preliminary data using novel approaches that provide exciting new insights into the
mechanisms of 5-HT neuroplasticity that will enlighten both basic and clinical science. These convergent findings
led us to postulate our Central Hypothesis that maladaptive 5-HT-raphe-striatal neurocircuit plasticity
precipitates and maintains LID. The overarching goal for our multi-investigator team is to identify the mechanisms
underlying the development of structural and functional maladaptation within the raphe-striatal circuit driving LID,
which in turn could lead to novel, optimized targets for intervention. We will fill this knowledge gap through the
pursuit of 3 independent, but inter-related Specific Aims. Our 3 Specific Aims will: 1) define the extent to which
DA denervation and/or L-DOPA treatment results in anatomical and functional reorganization of the 5-HT raphe-
striatal pathway in PD and experimental parkinsonism, 2) use projection-specific chemogenetic modulations to
determine the impact of the 5-HT raphe-striatal activity on L-DOPA-induced anti-parkinsonian efficacy and
dyskinesia, and 3) establish how regulating DA release from 5-HT raphe-striatal neurons prevents the
development of LID and associated maladaptive neuronal changes. The proposed cross-species investigation will
establish neuroplasticity within the 5-HT raphe-striatal circuit as a foremost factor in the development and expression
of LID and in so doing, identify optimal treatment strategies to improve the quality of life for millions of current and
prospective PD patients.

Grant Number: 5R01NS122226-04
NIH Institute/Center: NIH
Principal Investigator: CHRISTOPHER BISHOP